US 7,396,818 B2
Sulfotransferase inhibitor
Koji Kimata, Nagoya (Japan); and Hiroko Habuchi, Nagoya (Japan)
Assigned to Seikagaku Corporation, Chiyoda-ku, Tokyo (Japan)
Appl. No. 10/557,652
PCT Filed May 19, 2004, PCT No. PCT/JP2004/006750
§ 371(c)(1), (2), (4) Date Nov. 21, 2005,
PCT Pub. No. WO2004/100961, PCT Pub. Date Nov. 25, 2004.
Claims priority of application No. 2003-140867 (JP), filed on May 19, 2003.
Prior Publication US 2007/0066564 A1, Mar. 22, 2007
Int. Cl. A01N 43/04 (2006.01); A61K 31/70 (2006.01); C07H 15/00 (2006.01); C07H 15/06 (2006.01)
U.S. Cl. 514—25  [536/18.2] 4 Claims
 
1. A method of inhibiting a heparin/heparan sulfate sulfotransferase by contacting the heparin/heparan sulfate sulfotransferase with a hexuronic acid derivative represented by the following formula 1 or a salt thereof, wherein the heparin/heparan sulfate sulfotransferase has activity to transfer a sulfate group to a hydroxyl group at 6-position of a glucosamine residue or to a hydroxyl group at 2-position of a hexuronic acid residue in a heparin skeleton,

OG Complex Work Unit Drawing
wherein each of R1, R2, and R3 independently represent(s) SO3− or H, provided that at least one thereof represents SO3−; X represents OR4, R4 independently represents H, alkyl which may have a substituent selected from alkoxy group and acyloxy group, alkenyl, alkynyl, acyl, aryl, or aralkyl group; one of R5 and R6 represents COOH while the other represents H; and the wavy line represents α-glycosidic bond or β-glycosidic bond, wherein said acyl group is represented as —CO—R7 in which R7 represents a group selected from alkyl which may have a substituent selected from alkoxy group and acyloxy group, alkenyl, alkynyl, aryl, and aralkyl groups.